RemeGen Co. Ltd (REGMF PINK) stock market data APIs
$9.8437
0(0%)
as of January 6, 2026
Try our APIs with
free plan!
RemeGen Co. Ltd Financial Data Overview
Price chart is built with
Anychart
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Prev. Close
9.8437
Open
9.8437
High
9.8437
Low
9.8437
52 wk Range
1.5-12.525
Market Cap
5 529 M
Shares Outstanding
209 M
Revenue
2 228 M
EPS
-0.0251
Beta
0.683
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RemeGen Co. Ltd data using free add-ons & libraries
Get RemeGen Co. Ltd Fundamental Data
RemeGen Co. Ltd Fundamental data includes:
- Net Revenue: 2 228 M
- EBITDA: -636 457 088
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-27
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RemeGen Co. Ltd News
New
3 Asian Stocks That May Be Undervalued By Up To 41.4%
As global markets navigate a complex landscape, Asian indices have shown mixed performances with Japan's stock markets experiencing declines and China's manufacturing sector displaying modest improvem...
Asian Growth Companies With High Insider Ownership In January 2026
As we enter 2026, the Asian markets are navigating a complex landscape marked by mixed performances across major indices, with China showing signs of manufacturing recovery and South Korea experiencin...
Asian Market Value Picks Featuring 3 Stocks Trading Below Estimated Worth
As global markets grapple with concerns over AI valuations and economic uncertainties, Asian markets have mirrored this cautious sentiment, particularly in China where investor worries about frothy va...
Asian Growth Companies With Strong Insider Confidence November 2025
As Asian markets navigate a landscape marked by economic fluctuations and investor sentiment shifts, the focus on insider confidence in growth companies becomes increasingly relevant. In this article,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
